Interleukin-1 in COVID-19 Infection: Immunopathogenesis and Possible Therapeutic Perspective.
Viral Immunol
; 34(10): 679-688, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1560640
ABSTRACT
The newfound coronavirus disease 2019 (COVID-19), initiated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an international public health concern, threatening the lives of millions of people worldwide. The virus seems to have a propensity to infect older males, especially those with underlying diseases. The cytokine storm following hyperactivated immune responses due to SARS-CoV-2 infection is probably the crucial source of severe pneumonia that leads to acute lung injury, systemic inflammatory response syndrome, or acute respiratory distress syndrome, and finally multiple organ dysfunction syndromes, as well as death in many cases. Several studies revealed that interleukin (IL)-1ß levels were elevated during COVID-19 infection. In addition, the IL-1 cytokine family has a pivotal role in the induction of cytokine storm due to uncontrolled immune responses in COVID-19 infection. This article reviews the role of IL-1 in inflammation and utilization of IL-1 inhibitor agents in controlling the inflammatory outcomes initiated by SARS-CoV-2 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Interleukin-1
/
Cytokine Release Syndrome
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Viral Immunol
Journal subject:
Allergy and Immunology
/
Virology
Year:
2021
Document Type:
Article
Affiliation country:
Vim.2021.0071
Similar
MEDLINE
...
LILACS
LIS